Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBLG NASDAQ:MIRA NYSE:NNVC NASDAQ:PPBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBLGFibroBiologics$0.69+2.0%$0.77$0.58▼$5.54$27.18M-0.78313,552 shs140,934 shsMIRAMIRA Pharmaceuticals$1.74-3.6%$1.31$0.73▼$5.01$29.53M1.722.34 million shs628,466 shsNNVCNanoViricides$1.62-3.9%$1.47$0.94▼$2.55$25.80M0.88238,733 shs994,809 shsPPBTPurple Biotech$2.68+3.1%$2.45$2.00▼$13.95$6.94M0.41270,889 shs40,790 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBLGFibroBiologics0.00%+6.69%-3.48%-51.35%-85.08%MIRAMIRA Pharmaceuticals0.00%+40.63%+47.54%+108.09%+161.32%NNVCNanoViricides0.00%+20.43%+17.48%+29.23%-20.75%PPBTPurple Biotech0.00%+5.52%+11.59%-8.45%+259,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFBLGFibroBiologics3.4314 of 5 stars3.65.00.00.01.13.30.6MIRAMIRA Pharmaceuticals1.8229 of 5 stars3.73.00.00.00.60.00.6NNVCNanoViricides0.4307 of 5 stars0.03.00.00.03.10.00.0PPBTPurple Biotech2.0071 of 5 stars3.53.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBLGFibroBiologics 3.20Buy$13.001,797.81% UpsideMIRAMIRA Pharmaceuticals 3.33Buy$14.00706.92% UpsideNNVCNanoViricides 0.00N/AN/AN/APPBTPurple Biotech 3.00Buy$33.001,131.34% UpsideCurrent Analyst Ratings BreakdownLatest PPBT, MIRA, NNVC, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBLGFibroBiologicsN/AN/AN/AN/A$0.08 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$12.73 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBLGFibroBiologics-$11.16M-$0.21N/AN/AN/AN/A-1,022.04%-117.56%8/6/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/APPBTPurple Biotech-$7.24M-$2.62N/AN/AN/AN/A-17.84%-15.44%8/15/2025 (Estimated)Latest PPBT, MIRA, NNVC, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025N/APPBTPurple Biotech-$0.21N/AN/AN/AN/AN/A8/12/2025N/AMIRAMIRA Pharmaceuticals-$0.10N/AN/AN/AN/AN/A8/6/2025Q1 2025FBLGFibroBiologics-$0.11N/AN/AN/AN/AN/A5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBLGFibroBiologicsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBLGFibroBiologicsN/A1.141.14MIRAMIRA PharmaceuticalsN/A12.8612.86NNVCNanoViricidesN/A3.442.47PPBTPurple BiotechN/A2.722.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBLGFibroBiologicsN/AMIRAMIRA Pharmaceuticals35.16%NNVCNanoViricides10.30%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipFBLGFibroBiologics20.80%MIRAMIRA Pharmaceuticals6.65%NNVCNanoViricides4.60%PPBTPurple Biotech2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBLGFibroBiologics1039.68 million31.43 millionN/AMIRAMIRA Pharmaceuticals216.92 million15.80 millionNot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionablePPBTPurple Biotech202.59 million2.51 millionOptionablePPBT, MIRA, NNVC, and FBLG HeadlinesRecent News About These CompaniesPurple Biotech Stock Price History - Investing.comJuly 8, 2025 | investing.comPurple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual CongressJune 23, 2025 | globenewswire.comPurple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck CancerJune 17, 2025 | finance.yahoo.comPurple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody PlatformJune 4, 2025 | finance.yahoo.comH.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy RatingJune 1, 2025 | msn.comPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | finanznachrichten.dePurple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | globenewswire.comPurple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial ExcellenceMay 13, 2025 | nasdaq.comPurple Biotech appoints Shai Lankry as new CFOMay 13, 2025 | investing.comPurple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | finanznachrichten.dePurple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | globenewswire.comPurple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic CancerApril 30, 2025 | tipranks.comPurple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck CancersApril 28, 2025 | globenewswire.comPurple Biotech announces publication of study on potential of NT219April 17, 2025 | markets.businessinsider.comPurple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research MeetingMarch 28, 2025 | finance.yahoo.comPurple Biotech Unveils Updated Oncology Pipeline ProgressMarch 18, 2025 | tipranks.comPurple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 StudiesMarch 12, 2025 | nasdaq.comPurple Biotech reports Q4 EPS (26c) vs. ($3.80) last yearMarch 10, 2025 | markets.businessinsider.comPurple Biotech sees cash runway into mid-2026March 10, 2025 | markets.businessinsider.comPurple Biotech Reports Fourth Quarter and Full-Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPBT, MIRA, NNVC, and FBLG Company DescriptionsFibroBiologics NASDAQ:FBLG$0.68 +0.01 (+2.03%) As of 12:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.MIRA Pharmaceuticals NASDAQ:MIRA$1.74 -0.07 (-3.61%) As of 12:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.NanoViricides NYSE:NNVC$1.62 -0.07 (-3.87%) As of 12:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Purple Biotech NASDAQ:PPBT$2.68 +0.08 (+3.08%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
